Could it make Alzheimer鈥檚 worse? Animal studies suggest that an antibody similar to one being trialled in people for the treatment of Alzheimer鈥檚 might actually be harmful.
Antibodies are currently undergoing trials in humans, as they have been found to break down the sticky plaques that build up in the brain. But in mice with a version of Alzheimer鈥檚, antibodies that work the same way seem to make brain cells hyperactive and then eventually stop functioning.
Advertisement
鈥淲e think this is a possible mechanism for the failure of these antibodies in human trials,鈥� says Marc Busche of the Technical University of Munich, Germany.
Busche and his colleagues gave an antibody drug to mice with Alzheimer鈥檚-like disease and also to normal mice. After treatment, they found that mice with the disease had five times as many hyperactive brain cells than in treated normal mice.
Breaking up plaques
Alzheimer鈥檚 plaques form when protein pieces called beta amyloid clump together. Busche and his colleagues previously discovered that beta amyloid proteins can cause neurons to become hyperactive. They suggest that when the antibodies break up the plaques, it somehow aggravates this effect, making it worse than if the plaques remained intact.
In the wake of multiple failures trying to treat people with advanced Alzheimer鈥檚 disease, drug developers have switched to trying to detect and treat disease earlier.
So Busche and his team also studied the effect of the drug in mice with early-stage Alzheimer鈥檚. Even in these mice, which had no plaques in their brains, neurons became hyperactive and symptoms of the disease worsened.
Mice can be misleading
鈥淲e find that even in very young mice, prior to plaque deposition, there鈥檚 an increase in hyperactivity,鈥� says Busche. It鈥檚 not yet clear what process is causing the hyperactivity.
There鈥檚 no need to throw out these drugs just yet, though. Other researchers caution that mouse experiments have a
history of misleading results. 鈥淢ouse models are not perfect 鈥� we鈥檝e been curing animals of Alzheimer鈥檚 for years,鈥� says Maria Carrillo, chief scientific officer of the US charity .
Busche agrees that mouse models don鈥檛 mimic every aspect of human disease. 鈥淭reatments directed against amyloid beta are still promising,鈥� he says, 鈥渂ut in the end we might need a combination of several approaches.鈥�
Journal reference: Nature Neuroscience, DOI: 10.1038/nn.4163
(Image: Juan Gaertner/Science Photo Library)
